Top pharmaceutical legal firms, recognized for their expertise in litigation, IP, and regulatory compliance, include Covington & Burling, Arnold & Porter, Cooley LLP, Latham & Watkins, and Ropes & Gray. These firms are leaders in handling complex drug development, FDA regulation, and high-stakes product liability cases.
_______
The top pharmaceutical pricing middlemen, known as Pharmacy Benefit Managers (PBMs), are CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth Group). These "Big 3" firms dominate 80% of the U.S. market.
Rebate Aggregators (Group Purchasing Organizations)
These entities negotiate rebates with manufacturers on behalf of PBMs:
Federal Trade Commission (.gov)
Zinc Health Services (for CVS Caremark).
Ascent Health Services (for Express Scripts, Humana).
Emisar Pharma Services.
___
The top monoclonal antibody (mAb) manufacturers are dominated by pharmaceutical giants, led by Johnson & Johnson, Roche, Merck & Co, and Pfizer.
These companies command the market through blockbuster drugs for oncology and immunology, such as Keytruda, Darzalex, and Humira.
The market is rapidly growing, with a projected value of $451.89 billion by 2028.
___
The top oncology distributors in the U.S. are dominated by major, specialized, and full-service firms, with ASD Healthcare (a Cencora company) being the largest for specialty oncology products to health systems. McKesson Specialty Health is another leading distributor, while Besse Medical is a top provider for community oncology practices.
Distribution Network: The market is highly concentrated, with McKesson, Cencora, and Cardinal Health acting as the primary wholesalers.
Market Leaders in Oncology (Manufacturers):
Key players driving the oncology pipeline and product volume include Roche, Genentech, Merck, and AstraZeneca.
___
For me, Cytodyn can't afford to sell Leronlimab. The total loss would simply be too large. Above would be just some of the potential key ingredients of a corp building future.
Cost to build & or partner, is simply peanuts compared to selling @ even say $200b, or so.
Way too many direct/in-direct benefits LL /LL-PLS give.
LL/LL-PLS is the one you keep & cornerstone develop. Moving to a higher exchange.
_______
The top pharmaceutical pricing middlemen, known as Pharmacy Benefit Managers (PBMs), are CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth Group). These "Big 3" firms dominate 80% of the U.S. market.
Rebate Aggregators (Group Purchasing Organizations)
These entities negotiate rebates with manufacturers on behalf of PBMs:
Federal Trade Commission (.gov)
Zinc Health Services (for CVS Caremark).
Ascent Health Services (for Express Scripts, Humana).
Emisar Pharma Services.
___
The top monoclonal antibody (mAb) manufacturers are dominated by pharmaceutical giants, led by Johnson & Johnson, Roche, Merck & Co, and Pfizer.
These companies command the market through blockbuster drugs for oncology and immunology, such as Keytruda, Darzalex, and Humira.
The market is rapidly growing, with a projected value of $451.89 billion by 2028.
___
The top oncology distributors in the U.S. are dominated by major, specialized, and full-service firms, with ASD Healthcare (a Cencora company) being the largest for specialty oncology products to health systems. McKesson Specialty Health is another leading distributor, while Besse Medical is a top provider for community oncology practices.
Distribution Network: The market is highly concentrated, with McKesson, Cencora, and Cardinal Health acting as the primary wholesalers.
Market Leaders in Oncology (Manufacturers):
Key players driving the oncology pipeline and product volume include Roche, Genentech, Merck, and AstraZeneca.
___
For me, Cytodyn can't afford to sell Leronlimab. The total loss would simply be too large. Above would be just some of the potential key ingredients of a corp building future.
Cost to build & or partner, is simply peanuts compared to selling @ even say $200b, or so.
Way too many direct/in-direct benefits LL /LL-PLS give.
LL/LL-PLS is the one you keep & cornerstone develop. Moving to a higher exchange.
1
